Abstract

During atrial fibrillation (AF), the heart relies heavily on the atrio-ventricular (AV) node to regulate the heart rate. Thus, characterization of AV-nodal properties may provide valuable information for patient monitoring and prediction of rate control drug effects. In this work we present a network model consisting of the AV node, the bundle of His, and the Purkinje fibers, together with an associated workflow, for robust estimation of the model parameters from ECG. The model consists of two pathways, referred to as the slow and the fast pathway, interconnected at one end. Both pathways are composed of interacting nodes, with separate refractory periods and conduction delays determined by the stimulation history of each node. Together with this model, a fitness function based on the Poincaré plot accounting for dynamics in RR interval series and a problem specific genetic algorithm, are also presented. The robustness of the parameter estimates is evaluated using simulated data, based on clinical measurements from five AF patients. Results show that the proposed model and workflow could estimate the slow pathway parameters for the refractory period, and ΔRSP, with an error (mean ± std) of 10.3 ± 22 and −12.6 ± 26 ms, respectively, and the parameters for the conduction delay, and , with an error of 7 ± 35 and 4 ± 36 ms. Corresponding results for the fast pathway were 31.7 ± 65, −0.3 ± 77, 17 ± 29, and 43 ± 109 ms. These results suggest that both conduction delay and refractory period can be robustly estimated from non-invasive data with the proposed methodology. Furthermore, as an application example, the methodology was used to analyze ECG data from one patient at baseline and during treatment with Diltiazem, illustrating its potential to assess the effect of rate control drugs.

Highlights

  • Atrial fibrillation (AF) is the most widespread sustained cardiac arrhythmia with an estimated prevalence of 2–4% in the adult population (Benjamin et al, 2019)

  • In this work we present a network model of the AV node, able to estimate patient specific conduction delay and refractory period from ECG, building on previous work presented in Wallman and Sandberg (2018)

  • The robustness of the estimates is set in perspective by using the model to estimate AV node characteristics for one of the patients during both baseline and under influence of the calcium channel blocker drug Diltiazem

Read more

Summary

Introduction

Atrial fibrillation (AF) is the most widespread sustained cardiac arrhythmia with an estimated prevalence of 2–4% in the adult population (Benjamin et al, 2019). In order to reduce these effects, rate control drugs constitute one of the primary therapeutic options. Non-invasive AV Node Characterization in AF (Hindricks et al, 2020). These drugs are not designed to terminate AF, but rather to lower the heart rate. They do this by modulating the conduction through the AV node, preventing some electrical signals emanating from the atria from being transmitted to the ventricles, thereby reducing the ventricular activation rate. The choice of first-line rate control drugs can vary between beta-blockers and non-dihydropyridine calcium channel blockers, with digoxin as a second-line option (Hindricks et al, 2020). Patient specific characterization of AV node properties would be beneficial to achieve optimal rate control

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call